Project Grant R01HL178817
Award Date
6/4/25
Completion Date
4/30/30
Dollars Obligated
$605K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Delaware, USA
Similar Awards
This federal Project Grant award for $605,678 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research into a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. The research aims to explore the prospect that hypoxia activates a pathway operating in concert with hypoxia-inducible transcription factors (HIFs) to govern the hypoxic transcriptome. Specifically, the project will...
The federal Project Grant award for $121,773.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award is supporting research at the University of Arizona focused on understanding the role of the cytosolic kinase SGK1 in driving pathological cardiac hypertrophy, a precursor to heart failure. The project aims to determine the effects of depleting SGK1 on cardiac myocyte hypertrophy, as well as the impact of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $817,208 to The Broad Institute, Inc. for a project titled "From Genetic Basis to Mechanisms for Heart Failure." The project aims to leverage high-throughput functional genomics approaches, including cell painting and perturbation sequencing, to investigate the roles of genetic risk factors associated with heart...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $159,512 to The Leland Stanford Junior University to investigate the role of the unfolded protein response in genetic dilated cardiomyopathy. The research aims to uncover the cellular and molecular mechanisms by which impaired protein folding results in cardiac dysfunction, with a focus on identifying a novel therapeutic target...
This $785,198 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at Albert Einstein College of Medicine to investigate the role of chaperone-mediated autophagy (CMA) in cardiac fibrosis and repair following myocardial infarction. The research aims to study how CMA, a process that selectively degrades specific proteins, regulates the phenotypic transitions and functions of...
This federal Project Grant award of $159,512 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to discover effective strategies for mitigating the detrimental effects of cardiac fibrosis in diseases like dilated cardiomyopathy (DCM). The key objectives are to validate and describe the anti-fibrotic mechanisms of two previously identified drug compounds, CGS15943 and AM404, and correlate their efficacy...
This $1,088,500 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research program with three independent projects related to genetic and molecular mechanisms of heart disease. The first project aims to define microRNA targeting events and their biological relevance in the heart, as well as understand the clinical significance of genetic variants that alter cardiovascular microRNA...
This $1,660,873 Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of the eicosanoid-degrading enzyme 15-PGDH in cardiac fibrosis and heart failure. The grant recipient, The Regents of the University of Colorado, doing business as the University of Colorado-Denver, will conduct studies to test the hypothesis that inhibition of 15-PGDH can prevent and reverse...
This $758,862 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research aimed at preventing cardiac remodeling and heart failure after myocardial infarction. The grant will fund the development of a multimodal imaging-guided approach to deliver therapeutic hydrogels to the heart, with the goal of modulating myocardial mechanics and fibroblast activation to reduce post-infarct remodeling. Key...
This $587,249.00 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research to investigate the role of the CDK8 kinase in regulating cardiac transcription and its potential as a therapeutic target for pathological cardiac hypertrophy and heart failure. The key objectives of the project are to: 1) determine the therapeutic potential of small-molecule CDK8 inhibitors, 2)...